Abstract:Objective: Dynamic monitoring of CTCs/CSCs can assist in the diagnosis and prognosis of tumors. This study explores the diagnostic significance of microfluidic chip technology in the detection of CTCs/CSCs in clinical staging and metastasis of patients with non-small cell lung cancer (NSCLC). That lays a solid foundation for the use of microfluidic chips to monitor CTCs/CSCs for the stage and metastasis of patients with non-small cell lung cancer. Patients and methods: This study collected 80 patients with lung cancer from October 2017 to October 2018. Meanwhile, 30 healthy people and 30 patients with benign lung diseases were selected during the same period as the control group 1 and the control group 2, respectively. CellSearch (Huntington Valley, PA, USA) and microfluidic chip were used to detect CTCs, the sensitivities were recorded. ELISA methods were used to detect the concentrations of tumor markers VEGF-C, CEA, and CA125 in serum, and their association with CTCs and CSCs was analyzed. In addition, after 3 months, we followed up 40 patients with lung cancer, recorded their prognosis, and extracted peripheral blood to detect changes in their CTCs and CSCs. The CellSearch (Huntington Valley, PA, USA) system and the microfluidic chip system were used to detect the CTCs in patients with lung cancer, and the sensitivity and specificity of the patients were analyzed. The changes in CTCs and CSCs in the peripheral blood of the patient were recorded. Results: It can be seen that the positive rate of CTCs and CSCs is not significantly correlated with the patients' age, gender, pathological type (adenocarcinoma, squamous cell carcinoma), etc. They are significantly correlated with clinical stage (I + II and III + IV) and metastasis (metastasis and non-metastasis) (p<0.01). Then, we divided the patients into groups for testing, and analyzed the association between different groups of patients and CTCs and CSCs. Compared with control group 1 and control group 2, the positive rates of CTCs and CSCs in lung cancer metastasis group and non-metastasis group were significantly different (p<0.05). Compared with the control group 1 and control group 2, the positive rates of CTCs and CSCs in stage I + II and III + IV of lung cancer were significantly different (p<0.05). The positive rate was significantly higher in the cancer metastasis group (p<0.05). The concentrations of tumor markers VEGF-C, CEA, CA125 in the serum of patients were consistent with CTCs-negative and CTC-positive lung cancer, with significant differences (p<0.05). CSCs negative and CSCs positive patients have similar results. Subsequently, we analyzed the sensitivity and specificity of CSCs, CTCs, and tumor markers for the diagnosis of NSCLC. The results showed that the sensitivity of CSCs and CTCs to diagnose patients was significantly higher than that of tumor markers. Conclusions: This study shows that our microfluidic chip device can exhibit relatively good performance and can better detect CTCs and CSCs. Monitoring CTCs and CSCs of patients can provide a basis for judging the stage and metastasis of patients.

Combination Detection of Three Gene Markers Expressed in Circulating Cancer Cells of Non-Small Cell Lung Cancer

CEA, SCC and NSE levels in exhaled breath condensate--possible markers for early detection of lung cancer.

Detection of Micrometastases of Non-small Cell Lung Cancer by Using CK19 mRNA and LUNX mRNASpecific Reverse Transcription-polymerase Chain Reaction

[Detection of CK19 and CEA mRNA expression for the diagnosis of peripheral blood micrometastases in patients with non-small cell lung cancer].

[Significance of Combined Determination of CK19mRNA, Carcinoembryanic Antigen, Neuron-Specific Enolase, and Tissue Polypeptide Antigen in Peripheral Blood of Patients with Lung Cancer].

Detection of circulating cancer cells in lung cancer patients with a panel of marker genes.

[Combined Detection of CEA Mrna and CK 19 Mrna in Peripheral Blood Cells of Patients with Lung Cancer].

Identification of miRNA Biomarkers for Non-small Cell Lung Cancer using Microarray Datasets and Bioinformatics Analysis

Detection of Micrometastases of Lung Cancer by Using Lunx Mrna Specific Reverse Transcription-Polymerase Chain Reaction

Diagnostic Utility of LunX Mrna in Peripheral Blood and Pleural Fluid in Patients with Primary Non-Small Cell Lung Cancer

[The Value of Circulating Tumor Cells Detected by Chromosome Centromere Probe Identification in Diagnosis of Non-Small Cell Lung Cancer].

The diagnostic value of serum exosomal miRNA-587 combined with hypersensitive C-reactive protein as noninvasive biomarker in early-stage non-small cell lung cancer

[LUNX mRNA in regional lymph nodes of non-small cell lung cancer patients by RT-PCR and its clinical significance]

Diagnostic value of detection of lung-specific X protein gene mRNA in the peripheral blood of patients with lung cancer using real-time RT-PCR assay

Relation between peripheral blood active circulating tumor cell and clinical characteristics of non-small cell lung cancer

Altered Mir-143 and Mir-150 Expressions in Peripheral Blood Mononuclear Cells for Diagnosis of Non-Small Cell Lung Cancer.

Combined assay of Circulating Tumor DNA and Protein Biomarkers for early noninvasive detection and prognosis of Non-Small Cell Lung Cancer

Circulating miRNAs in Serum as Biomarkers for Early Diagnosis of Non-small Cell Lung Cancer

Detection of circulating genetically abnormal cells in peripheral blood for early diagnosis of non‐small cell lung cancer

Combination of circulating tumor cells with serum carcinoembryonic antigen enhances clinical prediction of non-small cell lung cancer

Detection of CTCs and CSCs in the staging and metastasis of non-small cell lung cancer based on microfluidic chip and the diagnostic significance